ATE471947T1 - Tat-cd4-hiv-hybridmoleküle und verwendungsverfahren dafür - Google Patents

Tat-cd4-hiv-hybridmoleküle und verwendungsverfahren dafür

Info

Publication number
ATE471947T1
ATE471947T1 AT06734349T AT06734349T ATE471947T1 AT E471947 T1 ATE471947 T1 AT E471947T1 AT 06734349 T AT06734349 T AT 06734349T AT 06734349 T AT06734349 T AT 06734349T AT E471947 T1 ATE471947 T1 AT E471947T1
Authority
AT
Austria
Prior art keywords
hybrid molecules
methods
tat
hiv
polypeptides
Prior art date
Application number
AT06734349T
Other languages
English (en)
Inventor
Susan Barnett
Rino Rappuoli
Victoria Sharma
Indresh Srivastava
Original Assignee
Novartis Vaccines & Diagnostic
Susan Barnett
Rino Rappuoli
Victoria Sharma
Indresh Srivastava
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic, Susan Barnett, Rino Rappuoli, Victoria Sharma, Indresh Srivastava filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE471947T1 publication Critical patent/ATE471947T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT06734349T 2005-02-03 2006-02-03 Tat-cd4-hiv-hybridmoleküle und verwendungsverfahren dafür ATE471947T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65063505P 2005-02-03 2005-02-03
PCT/US2006/003935 WO2006084179A2 (en) 2005-02-03 2006-02-03 Hiv tat-cd4 hybried molecules and methods of use thereof

Publications (1)

Publication Number Publication Date
ATE471947T1 true ATE471947T1 (de) 2010-07-15

Family

ID=36777987

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06734349T ATE471947T1 (de) 2005-02-03 2006-02-03 Tat-cd4-hiv-hybridmoleküle und verwendungsverfahren dafür

Country Status (8)

Country Link
US (2) US8168194B2 (de)
EP (1) EP1893650B1 (de)
CN (1) CN101146827A (de)
AT (1) ATE471947T1 (de)
CA (1) CA2597040A1 (de)
DE (1) DE602006015050D1 (de)
WO (1) WO2006084179A2 (de)
ZA (1) ZA200707138B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006085959A2 (en) 2004-06-08 2006-08-17 Novartis Vaccines And Diagnostics Inc. Fusion proteins comprising cd4 minimal modules and methods of use thereof
ATE471947T1 (de) 2005-02-03 2010-07-15 Novartis Vaccines & Diagnostic Tat-cd4-hiv-hybridmoleküle und verwendungsverfahren dafür
DK2120987T3 (en) * 2007-03-02 2014-02-24 Nono Inc Treatment of stroke and other diseases without inhibiting N-type calcium channels
EP2706356A1 (de) * 2012-09-06 2014-03-12 Laboratorios Del. Dr. Esteve, S.A. Verfahren zur Identifizierung HIV-neutralisierender Antikörper
CN111303243B (zh) * 2020-02-25 2021-07-27 徐州医科大学 治疗缺血性脑损伤的小肽tat-akpd及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US6004781A (en) 1988-01-22 1999-12-21 The General Hospital Corporation Nucleic acid encoding Ig-CD4 fusion proteins
WO1993000103A1 (en) 1991-06-21 1993-01-07 The Wistar Institute Of Anatomy And Biology Chimeric envelope proteins for viral targeting
US5817767A (en) 1993-02-24 1998-10-06 Progenics Pharmaceuticals, Inc. Synergistic composition of CD4-based protein and anti-HIV-1 antibody, and methods of using same
EP0699077B1 (de) 1993-05-07 2001-10-31 Akzo Nobel N.V. Hiv immunogene komplexe
AU3241095A (en) 1994-07-29 1996-03-04 Chiron Corporation Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same
JP4776075B2 (ja) 1998-12-31 2011-09-21 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 改変ｈｉｖｅｎｖポリペプチド
AU2221600A (en) 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
US20020177551A1 (en) 2000-05-31 2002-11-28 Terman David S. Compositions and methods for treatment of neoplastic disease
FR2799974B1 (fr) 1999-10-25 2001-11-30 Aventis Pasteur Complexe deglycosyle proteine env/cd4 et son utilisation pour la vaccination contre le vih
CA2458995C (en) 2001-08-31 2013-04-30 Chiron Corporation Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
AU2003301556A1 (en) 2002-05-07 2004-05-13 Chiron Corporation Hiv envelope-cd4 complexes and hybrids
GB0218817D0 (en) * 2002-08-13 2002-09-18 San Raffaele Centro Fond Pharmaceutical compounds
WO2006085959A2 (en) * 2004-06-08 2006-08-17 Novartis Vaccines And Diagnostics Inc. Fusion proteins comprising cd4 minimal modules and methods of use thereof
ATE471947T1 (de) 2005-02-03 2010-07-15 Novartis Vaccines & Diagnostic Tat-cd4-hiv-hybridmoleküle und verwendungsverfahren dafür

Also Published As

Publication number Publication date
CA2597040A1 (en) 2006-08-10
ZA200707138B (en) 2008-11-26
WO2006084179A2 (en) 2006-08-10
US8637044B2 (en) 2014-01-28
EP1893650A2 (de) 2008-03-05
DE602006015050D1 (de) 2010-08-05
US20080317779A1 (en) 2008-12-25
US8168194B2 (en) 2012-05-01
EP1893650B1 (de) 2010-06-23
CN101146827A (zh) 2008-03-19
US20120183557A1 (en) 2012-07-19
WO2006084179A3 (en) 2006-12-14

Similar Documents

Publication Publication Date Title
CY1121327T1 (el) Τροποποιημενα αντισωματα anti-il-23p19
DE602007010664D1 (de) P53 aktivierende benzoylharnstoff- und benzoylthioharnstoff-verbindungen
NO20082531L (no) Neuropilinantagonister
BR112012000167A2 (pt) Catalisadores de hidrossililação
WO2007087549A3 (en) Chemical compounds
ES2367583T5 (es) Hidrogeles con enlaces de hidrogeno.
TW200621754A (en) Chemical compounds
EA201300246A1 (ru) Ингибиторы тирозинкиназы брутона
EA201590910A1 (ru) Белки на основе структурного домена фибронектина, связывающие pcsk9
EP2350129A4 (de) Pd1-antagonistenzusammensetzungen und verfahren zu ihrer verwendung
MX2007008160A (es) Liquidos ionicos estables base.
WO2008089397A3 (en) Adrb2 cancer markers
TR201909522T4 (tr) Anti-tümör aktivitesine sahip bir nonapeptit.
EP1983002A3 (de) Tyrosinphosphorylations-Stellen und spezifische Antikörper
EA200701825A1 (ru) Вакцины против хламидиоза
CL2011000116A1 (es) Compuestos derivados de imidazo[1,2-a]piridina; procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; y uso en el tratamiento del cancer.
EP2173337A4 (de) Phosphaplatine und ihre verwendung bei der behandlung von gegen cisplantin und carboplatin resistenten krebserkrankungen
WO2007027999A3 (en) Chemical compounds
ZA200707138B (en) HIV Tat-CD4 hybried molecules and methods of use thereof
MX2009009743A (es) Polvos para reconstitucion.
ATE483720T1 (de) Verbindungen enthaltend organofluorochlorophosphatanionen
TW200641091A (en) Organometallic complexes
EA200701172A1 (ru) 2-алкокси-3,4,5-тригидроксиалкиламиды, их получение, композиции, их содержащие, и применение
CL2008001322A1 (es) Compuestos derivados de triazolil-aminopirimidina, sustituida con heterociclos; composicion farmaceutica; y uso en el tratamiento del cancer.
SG153796A1 (en) Fusion proteins comprising cd4 minimal modules and methods of use thereof

Legal Events

Date Code Title Description
EEIH Change in the person of patent owner
UEP Publication of translation of european patent specification

Ref document number: 1893650

Country of ref document: EP